References and Further Reading
Abba, M. C., Drake, J. A., Hawkins, K. A., et al. (2004). Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Research, 6, R499–R513.
Abba, M. C., Gong, T., Lu, Y., et al. (2015). A molecular portrait of high-grade ductal carcinoma in situ. Cancer Research, 75, 3980–3990.
Adriance, M. C., Inman, J. L., Petersen, O. W., et al. (2005). Myoepithelial cells: Good fences make good neighbors. Breast Cancer Research, 7, 190–197.
Allinen, M., Beroukhim, R., Cai, L., et al. (2004). Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6, 17–32.
Anderson, W. F., & Devesa, S. S. (2005). In situ male breast carcinoma in the surveillance, epidemiology, and end results database of the National Cancer Institute. Cancer, 104, 1733–1741.
Aubele, M., Cummings, M., Walsch, A., et al. (2000). Heterogeneous chromosomal aberrations in intraductal breast lesions adjacent to invasive carcinoma. Analytical Cellular Pathology, 20, 17–24.
Bellamy, C. O., McDonald, C., Salter, D. M., et al. (1993). Noninvasive ductal carcinoma of the breast: The relevance of histologic categorization. Human Pathology, 24, 16–23.
Böcker, W. (2006). Preneoplasia of the breast. A new conceptual approach to proliferative breast disease. Munich: Elsevier GmbH.
Bombonati, A., & Sgroi, D. C. (2011). The molecular pathology of breast cancer progression. Journal of Pathology, 223, 307–317.
Bratthauer, G. L., Moinfar, F., Stamatakos, M. D., et al. (2002). Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Human Pathology, 33, 620–627.
Casasent, A. K., Edgerton, M., & Navin, N. E. (2017). Genome evolution in ductal carcinoma in situ: Invasion of the clones. Journal of Pathology, 241, 208–218.
Castellano, I., Marchiò, C., Tomatis, M., et al. (2010). Micropapillary ductal carcinoma in situ of the breast: An inter-institutional study. Modern Pathology, 23, 260–269.
Comparison of Operative to Monitoring and Endocrine Therapy (COMET). Trial For Low Risk DCIS (COMET). https://clinicaltrials.gov/ct2/show/NCT02926911
Curigliano, G., Disalvatore, D., Esposito, A., et al. (2015). Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Annals of Oncology, 26, 682–687.
Decensi, A., Puntoni, M., Pruneri, G., et al. (2011). Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prevention Research, 4, 1181–1189.
Elsayegh, N., Kuerer, H. M., Lin, H., et al. (2014). Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Annals of Oncology, 21, 3466–3472.
Elshof, L. E., Tryfonidis, K., Slaets, L., et al. (2015). Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – the LORD study. European Journal of Cancer, 51, 1497–1510.
EORTC Breast Cancer Cooperative Group, EORTC Radiotherapy Group, Bijker, N., et al. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology, 24, 3381–3387.
Erbas, B., Provenzano, E., Armes, J., et al. (2006). The natural history of ductal carcinoma in situ of the breast: A review. Breast Cancer Research and Treatment, 97, 135–144.
Ernster, V. L., & Barclay, J. (1997). Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: A dilemma. Journal of the National Cancer Institute Monographs, 22, 151–156.
Ernster, V. L., Barclay, J., Kerlikowske, K., et al. (2000). Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Archives of Internal Medicine, 160, 953–958.
Ernster, V. L., Ballard-Barbash, R., Barlow, W. E., et al. (2002). Detection of ductal carcinoma in situ in women undergoing screening mammography. Journal of the National Cancer Institute, 94, 1546–1554.
Francis, A., Fallowfield, L., & Rea, D. (2015). The LORIS trial: Addressing overtreatment of ductal carcinoma in situ. Clinical Oncology, 27, 6–8.
Galimberti, V., Monti, S., & Mastropasqua, M. G. (2013). DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast, 22, 431–435.
Giuseppetti, G. M., Boria, F., & Baldassare, S. (2018). DCIS imaging. In C. Mariotti (Ed.), Ductal carcinoma in situ (pp. 39–57). Cham: Springer.
Greenwood, H. I., Heller, S. L., Kim, S., et al. (2013). Ductal carcinoma in situ of the breasts: Review of MR imaging features. Radiographics, 33, 1569–1588.
Hannafon, B. N., Sebastiani, P., de las Morenas, A., et al. (2011). Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Research, 13, R24.
Holmes, P., Lloyd, J., Chervoneva, I., et al. (2011). Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer, 117, 3650–3657.
Kim, S. Y., Jung, S. H., Kim, M. S., et al. (2015). Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget, 6, 7597–7607.
King, M. T., Winters, Z. E., Olivotto, I. A., et al. (2017). Patient-reported outcomes in ductal carcinoma in situ: A systematic review. European Journal of Cancer, 71, 95–108.
Kong, I., Narod, S. A., Taylor, C., et al. (2014). Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: A population-based outcomes analysis. Current Oncology, 21, e96–e104.
Kuerer, H. M., Buzdar, A. U., Mittendorf, E. A., et al. (2011). Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 117, 39–47.
Lakhani, S. R., Ellis, I. O., Schnitt, S. J., et al. (2012). WHO classification of tumors of the breast. Lyon: International Agency for Research on Cancer.
Lopez-Garcia, M. A., Geyer, F. C., Lacroix-Triki, M., et al. (2010). Breast cancer precursors revisited: Molecular features and progression pathways. Histopathology, 57, 171–192.
Lyman, G. H., Temin, S., Edge, S. B., et al. (2014). Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 32, 1365–1383.
Mardekian, S. K., Bombonati, A., & Palazzo, J. P. (2016). Ductal carcinoma in situ of the breast: The importance of morphologic and molecular interactions. Human Pathology, 49, 114–123.
Margolese, R. G., Cecchini, R. S., Julian, T. B., et al. (2016). Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. Lancet, 387, 849–856.
McCormick, B., Winter, K., Hudis, C., et al. (2015). RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. Journal of Clinical Oncology, 33, 709–715.
Mustonen, M., Raunio, H., Pääkkö, P., et al. (1997). The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology, 31, 347–354.
NCCN. (2015). Guidelines: https://www.nccn.org/professionals/physician_gls/default.aspx
Page, D. L., & Rogers, L. W. (1992). Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathology, 23, 1095–1097.
Patchefsky, A. S., Schwartz, G. F., Finkelstein, S. D., et al. (1989). Heterogeneity of intraductal carcinoma of the breast. Cancer, 63, 731–741.
Pilewskie, M., & Morrow, M. (2018). Margins in breast cancer: How much is enough? Cancer, 124, 1335–1341.
Pluchinotta, A. (2018). History of the DCIS of the breast and the evolution of knowledge based on ductal tree anatomy. In C. Mariotti (Ed.), Ductal Carcinoma in situ (pp. 1–23). Cham: Springer.
Polyak, K., & Hu, M. (2005). Do myoepithelial cells hold the key for breast tumor progression? Journal of Mammary Gland Biology and Neoplasia, 10, 231–247.
Rakha, E. A., Miligy, I. M., Gorringe, K. L., et al. (2017). Invasion in breast lesions: The role of the epithelial-stroma barrier. Histopathology, 72, 1075. https://doi.org/10.1111/his.13446.
Ravaioli, S., Tumedei, M. M., Foca, F., et al. (2017). Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy. International Journal of Experimental Pathology, 98, 289–295.
Reis-Filho, J. S., & Lakhani, S. R. (2003). The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions. Breast Cancer Research, 5, 313–319.
Reis-Filho, J. S., Simpson, P. T., Gale, T., et al. (2005). The molecular genetics of breast cancer: The contribution of comparative genomic hybridization. Pathology, Research and Practice, 201, 713–725.
Rominger, M., Berg, D., Frauenfelder, T., et al. (2016). Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer? European Radiology, 26, 1457–1465.
Rutter, C. E., Park, H. S., Killelea, B. K., et al. (2015). Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States. Annals of Surgical Oncology, 22, 2378–2386.
Shackney, S. E., & Silverman, J. F. (2003). Molecular evolutionary patterns in breast cancer. Advances in Anatomic Pathology, 10, 278–290.
Siziopikou, K. P., Anderson, S. J., Cobleigh, M. A., et al. (2013). Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Research and Treatment, 142, 415–421.
Solin, L. J., Gray, R., Baehner, F. L., et al. (2013). A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. Journal of the National Cancer Institute, 105, 701–710.
Staerkle, R. F., Lenzlinger, P. M., Suter, S. L., et al. (2006). Synchronous bilateral ductal carcinoma in situ of the male breast associated with gynecomastia in a 30-year-old patient following repeated injections of stanozolol. Breast Cancer Research and Treatment, 97, 173–176.
Surveillance, Epidemiology, and End Results (SEER) Program. (2014). National Cancer Institute. https://seer.cancer.gov/csr/1975_2014/
Tavassoli, F. A., & Devilee, P. (2003). World Health Organization classification of tumors of the breast. Lyon: International Agency for Research on Cancer.
Tot, T., & Gere, M. (2008). Radiological-pathological correlation in diagnosing breast carcinoma: The role of pathology in the multimodality era. Pathology & Oncology Research, 14, 173–178.
Verkooijen, H. M., Fioretta, G., De Wolf, C., et al. (2002). Management of women with ductal carcinoma in situ of the breast: A population-based study. Annals of Oncology, 13, 1236–1245.
Vincent-Salomon, A., Lucchesi, C., Gruel, N., et al. (2008). Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clinical Cancer Research, 14, 1956–1965.
Volinia, S., Galasso, M., Sana, M. E., et al. (2012). Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proceedings of the National Academy of Sciences of the United States of America, 109, 3024–3029.
Wai, E. S., Lesperance, M. L., Alexander, C. S., et al. (2011). Predictors of local recurrence in a population-based cohort of women with ductal carcinoma in situ treated with breast conserving surgery alone. Annals of Surgical Oncology, 18, 119–124.
Wapnir, I. L., Dignam, J. J., Fisher, B., et al. (2011). Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. Journal of the National Cancer Institute, 103, 478–488.
Yates, L. R., Gerstung, M., Knappskog, S., et al. (2015). Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature Medicine, 21, 751–759.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Castellano, I., Metovic, J. (2018). Ductal Carcinoma In Situ. In: van Krieken, J. (eds) Encyclopedia of Pathology. Encyclopedia of Pathology. Springer, Cham. https://doi.org/10.1007/978-3-319-28845-1_4706-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-28845-1_4706-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28845-1
Online ISBN: 978-3-319-28845-1
eBook Packages: Springer Reference MedicineReference Module Medicine